1. Home
  2. STTK vs PROV Comparison

STTK vs PROV Comparison

Compare STTK & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.95

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

N/A

Current Price

$16.05

Market Cap

103.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
PROV
Founded
2016
1956
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
103.6M
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
STTK
PROV
Price
$3.95
$16.05
Analyst Decision
Buy
Hold
Analyst Count
7
2
Target Price
$6.20
$16.25
AVG Volume (30 Days)
319.7K
5.0K
Earning Date
01-01-0001
04-28-2026
Dividend Yield
N/A
3.50%
EPS Growth
27.32
N/A
EPS
N/A
0.47
Revenue
$5,721,000.00
N/A
Revenue This Year
N/A
$4.14
Revenue Next Year
N/A
$3.70
P/E Ratio
N/A
$34.28
Revenue Growth
245.26
N/A
52 Week Low
$0.69
$13.50
52 Week High
$4.89
$16.64

Technical Indicators

Market Signals
Indicator
STTK
PROV
Relative Strength Index (RSI) 46.85 46.74
Support Level $3.52 $15.95
Resistance Level $4.23 $16.30
Average True Range (ATR) 0.28 0.26
MACD -0.02 -0.02
Stochastic Oscillator 23.85 33.10

Price Performance

Historical Comparison
STTK
PROV

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

Share on Social Networks: